Sitagliptin, as a DPP-4 inhibitor, prolongs the activity of natural GLP-1 and enhances Aβ degradation, potentially exerting a beneficial effect in alleviating cognitive impairment associated with Alzheimer’s disease [194]. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.